Introduction: Pasireotide is a somatostatin analog (SSA) that targets somatostatin receptor subtypes 1-3 and 5. An earlier phase I study showed antitumor activity of everolimus+pasireotide LAR (EVE+PAS) in NET.
Aim(s): To assess the efficacy and safety of EVE+PAS compared to EVE alone in patients (pts) with advanced, progressive pNET.
Materials and methods: We performed a randomized, open-label, phase II study of EVE±PAS in pts with advanced G1/G2 pNET; stratified by prior SSA use, baseline CgA and/or NSE. Primary endpoint was PFS. Secondary endpoints included RECIST-defined tumor response rate, overall survival (OS), and safety.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Matthew H Kulke
Kulke M H
, Ruszniewski P
, Van Cutsem E
, Valle J
, De Herder W
, Pavel M
, Degtyarev E
, Lam D
, Salazar R
, Borbath I
, Fazio N
, Lombard-Bohas C
, Yao J C
To read results and conclusion, please login ...
Further abstracts you may be interested in